We therefore searched for additional drug targets concentrating on epigenetic modifiers as several of the co-occurring mutations in MPN patients affect epigenetic enzymes, for example TET2, DNMT3A and ASXL1. Here, ASXL1 is linked to myeloproliferative disorder.